Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adult human mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Clínica Universidad de Navarra
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous adult human mesenchymal stem cells (specifically bone marrow-derived, BM-MSCs) are an investigational cell therapy developed by the Instituto de Investigación Biomédica de Salamanca (IBSAL) in collaboration with the Clínica Universidad de Navarra and other Spanish centers. This advanced therapy medicinal product (ATMP) involves the extraction of a patient's own bone marrow, followed by the expansion of mesenchymal stem cells under Good Manufacturing Practice (GMP) conditions. The expanded cells are then administered via intra-articular injection into the knee. The therapy is designed to treat knee osteoarthritis by leveraging the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs, which aim to modify the joint microenvironment and promote cartilage repair. It has progressed to Phase III clinical trials in Spain, comparing its efficacy against allogeneic MSCs and hyaluronic acid.
- Other names
- autologous bone marrow mesenchymal stromal cellsautologous bone marrow-derived mesenchymal stem cellsBM-MSCsautologous MSCs
Beyond the preview
Go deeper on autologous adult human mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adult human mesenchymal stem cells.